Indeed, the LSD1 inhibitor ORY-1001 is under clinical investigation in ALL and AML, in which inhibition of LSD1 was pro-differentiative, however not sufficient to induce cell death as monotherapy [275]. Here, KDM1A is linked to acute myeloid leukemia.